Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Tadalafil for Duchenne Muscular Dystrophy
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 331
- Registration Number
- NCT01865084
- Locations
- 🇵🇷
University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico
🇺🇸University of California, Davis - Health Systems, Sacramento, California, United States
🇺🇸Children's Hospital, Aurora, Colorado, United States
A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT01859078
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 458
- Registration Number
- NCT01855919
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan
A Multiple Dose Study of LY3023703 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT01849055
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study of LY3084077 in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PlaceboDrug: LY3084077
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 43
- Registration Number
- NCT01846702
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore
A Study of LY3002813 in Participants With Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Biological: LY3002813-IVDrug: Placebo-IVBiological: LY3002813-SC
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 63
- Registration Number
- NCT01837641
- Locations
- 🇺🇸
Collaborative Neuroscience Network - CNS, Long Beach, California, United States
🇺🇸Compass Research, Orlando, Florida, United States
🇺🇸Atlanta Center of Medical Research, Atlanta, Georgia, United States
The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01836198
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT01836185
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States
A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 17
- Registration Number
- NCT01825876
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States
A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT01825889
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Paul, Minnesota, United States